BIOMAT Database Logo BIOMAT Database Logo

Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection. 2005

Mark A Wainberg, and James P C Sawyer, and Julio S G Montaner, and Robert L Murphy, and Daniel R Kuritzkes, and Francois Raffi
McGill University AIDS Center, Lady Davis Institute-Jewish General Hospital, Montreal, QC, Canada. mark.wainberg@mcgill.ca

There is a need for new antiretroviral drugs with activity against HIV isolates resistant to currently available agents and improved short and long-term tolerability profiles. Clinical trial designs for nucleotide and nucleoside reverse transcriptase inhibitors (NRTIs) are restricted by the characteristics of these agents (for example, their cross-resistance, resistance threshold and interaction profiles), the ethical need to ensure that patients are not maintained on suboptimal regimens, and regulatory requirements (for example, with regards to trial designs and patient populations). For example, consideration of cross-resistance profiles must influence the way in which an NRTI in development is sequenced to minimize any impact on future treatment options. The resistance threshold is determined by the number of mutations required to diminish sensitivity to a given drug. Pharmacokinetic or pharmacodynamic interactions restrict how NRTIs may be combined during clinical development. Doses may be selected on the basis of results from short-term monotherapy studies in treatment-naive patients, but such studies cannot establish the long-term efficacy or tolerability of new agents used in combination regimens. Confirmatory studies in treatment-naive populations do not meet the medical and regulatory needs for clinical data in treatment-experienced populations, while studies in treatment-experienced populations are subject to numerous clinical and logistical difficulties. Intensification, switch and hybrid study designs all offer suitable approaches to the evaluation of NRTIs with novel resistance profiles. Switch studies are particularly useful for agents with resistance profiles that suggest a specific sequencing approach in treatment and for those with the potential, based on pharmacokinetic data, for interactions with other agents. The successful development of new NRTIs will depend upon a thorough appreciation of these many and complex issues, not only among those involved in the design of clinical studies, but also those contributing to their review and conduct.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012449 Safety Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property. Safeties
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse

Related Publications

Mark A Wainberg, and James P C Sawyer, and Julio S G Montaner, and Robert L Murphy, and Daniel R Kuritzkes, and Francois Raffi
HIV nucleoside reverse transcriptase inhibitors.
October 2022, European journal of medicinal chemistry,
Mark A Wainberg, and James P C Sawyer, and Julio S G Montaner, and Robert L Murphy, and Daniel R Kuritzkes, and Francois Raffi
New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections.
October 2004, Current opinion in pharmacology,
Mark A Wainberg, and James P C Sawyer, and Julio S G Montaner, and Robert L Murphy, and Daniel R Kuritzkes, and Francois Raffi
Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.
January 2012, Expert opinion on pharmacotherapy,
Mark A Wainberg, and James P C Sawyer, and Julio S G Montaner, and Robert L Murphy, and Daniel R Kuritzkes, and Francois Raffi
New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections.
October 2004, Current opinion in pharmacology,
Mark A Wainberg, and James P C Sawyer, and Julio S G Montaner, and Robert L Murphy, and Daniel R Kuritzkes, and Francois Raffi
Nucleoside reverse transcriptase inhibitors and HIV mutagenesis.
October 2003, The Journal of antimicrobial chemotherapy,
Mark A Wainberg, and James P C Sawyer, and Julio S G Montaner, and Robert L Murphy, and Daniel R Kuritzkes, and Francois Raffi
[Non-nucleoside inhibitors of reverse transcriptase in therapy of HIV-infection].
January 2005, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
Mark A Wainberg, and James P C Sawyer, and Julio S G Montaner, and Robert L Murphy, and Daniel R Kuritzkes, and Francois Raffi
Search for new non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-1 RT).
January 2002, Acta poloniae pharmaceutica,
Mark A Wainberg, and James P C Sawyer, and Julio S G Montaner, and Robert L Murphy, and Daniel R Kuritzkes, and Francois Raffi
Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data.
July 2008, Current opinion in drug discovery & development,
Mark A Wainberg, and James P C Sawyer, and Julio S G Montaner, and Robert L Murphy, and Daniel R Kuritzkes, and Francois Raffi
Non-nucleoside inhibitors of HIV reverse transcriptase: screening successes--clinical failures.
July 1992, Drug design and discovery,
Mark A Wainberg, and James P C Sawyer, and Julio S G Montaner, and Robert L Murphy, and Daniel R Kuritzkes, and Francois Raffi
[HIV resistance to non-nucleoside reverse transcriptase inhibitors].
August 2006, Virologie (Montrouge, France),
Copied contents to your clipboard!